Menopause care has undergone a measurable shift over the years. In the early 2000s, findings from the Women’s Health Initiative linked hormone replacement therapy (HRT) to increased risks of breast cancer, stroke and blood clots, leading to a sharp decline in its use. Now that narrative is shifting.
More recent research and updated clinical guidance from organizations like the Food and Drug Administration are now reshaping how it is evaluated and prescribed. As of late 2025, the FDA has removed the “black box” warnings from many menopause hormone therapy products.
